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Introduction: Positron emission tomography (PET) imaging with fluorine-18-
fluorodeoxyglucose (18F-FDG) is widely known for its use in the diagnosis and tracking 
of primary and metastatic tumors via uptake and retention of the radiopharmaceutical by 
hypermetabolic cells. 18F-FDG is also used to study the normal physiology of glucose 
uptake, metabolism, and muscle activity during and after exercise.
Background: A pilot study adding PET imaging to the diagnostic evaluation of canine 
patients undergoing computed tomography (CT) for mild or intermittent thoracic and pel-
vic limb lameness is ongoing. Dogs with an observable (grade 1–2/5) lameness that have 
undergone routine radiography and complete physical examination by  board-certified 
veterinary surgeons and sports medicine and rehabilitation specialists are enrolled. Each 
patient undergoes leash walking for 15 min prior to premedication and induction of gen-
eral anesthesia for the PET–CT examination. 18F-FDG is injected intravenously, and a 
whole-body PET examination is conducted after 1 h of radiopharmaceutical uptake time. 
Standard algorithm, whole-body pre- and post-contrast CT examinations, and focused, 
standard, and bone algorithm CT scans of the thoracic or pelvic limb areas of interest are 
obtained concurrently. Abnormal PET–CT findings are further investigated with additional 
diagnostic imaging or at surgery (e.g., ultrasound, MRI, and arthroscopy).
Discussion: This case report uses a canine patient referred for thoracic limb lameness 
to illustrate the role of advanced imaging in a diagnostic plan and to discuss a rec-
ommended PET–CT procedure for lameness evaluation. The PET–CT imaging protocol 
recommended in this report was designed to significantly enhance a routine thoracic 
limb CT examination and to identify areas of muscle, tendon, or ligament overuse, 
inflammation, or injury for further diagnostic procedures or definitive treatment.
Concluding remarks: 18F-FDG PET–CT adds valuable physiologic and anatomic 
information to the diagnostic evaluation of patients presenting with indistinct or inter-
mittent clinical signs of musculoskeletal inflammation or injury. In addition, tailoring the 
PET acquisition and radiopharmaceutical parameters allows for detailed information 
gathering to more closely assess normal and abnormal physiology, unlocking a new 
frontier in the study of canine athletic injury and optimal performance.
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INtRoDUCtIoN
An 8.5-year-old castrated male, 20.9 kg, Chow-mix dog was pre-
sented to the Small Animal Sports Medicine and Rehabilitation 
Service for evaluation of a mild, intermittent right thoracic limb 
lameness of approximately 1-year duration. The patient history 
includes hip dysplasia with mild degenerative joint disease of 
both coxofemoral joints and grade 1–2/4 left-sided systolic heart 
murmur. Previous radiographs of the right shoulder and elbow 
were normal, and routine laboratory tests of blood and urine were 
also within normal limits. On orthopedic examination, he had a 
grade 1/5 right thoracic limb lameness at the trot and intermittent 
discomfort on Campbell’s test with normal range of motion and 
no joint effusion. Campbell’s test is based on a study evaluating 
collateral ligament integrity by supinating and pronating the 
carpus when the elbow and carpus are flexed in a 90° position (1). 
Modifications also include applying gentle pressure to the medial 
compartment and subjectively assessing patient reaction (2). The 
patient also had mild thickening at the distal insertion of the right 
flexor carpi ulnaris (FCU) tendon.
Challenging orthopedic and sports medicine cases are often 
referred for advanced imaging after routine diagnostic procedures 
are performed by the referring veterinarian. Magnetic resonance 
imaging (MRI) and computed tomography (CT) are frequently 
the next imaging procedures of choice. At our institution, a 
pilot study adding positron emission tomography (PET) to the 
diagnostic evaluation of canine patients undergoing CT as part 
of the normal diagnostic plan for mild or intermittent thoracic or 
pelvic limb lameness is ongoing. On the morning of the PET–CT 
examination, the patient was leash-walked for 15  min prior to 
premedication and induction of general anesthesia. The fluorine-
18-fluorodeoxyglucose (18F-FDG) was injected intravenously, 
and a whole-body PET examination was conducted after 1 h of 
radiopharmaceutical uptake time. Increased radiopharmaceuti-
cal uptake (IRU) was identified in the FCU muscle of the right 
antebrachium, and a slight increase in muscle size and density 
(approximately 20 HU) was noted in corresponding CT images. A 
faint ring of contrast enhancement corresponding to a 5-mm area 
of the most intense radiopharmaceutical uptake was also noted. 
A diagnostic ultrasound examination performed the following 
day revealed a hypoechoic region consistent with muscle tear-
ing within the right FCU muscle. Patient discharge instructions 
included: daily stretching of the thoracic limb muscles, restricted 
activity within the home (e.g., no running, jumping, stairs, or 
rough play), leash walks of no more than 10  min duration for 
6 weeks, and a NSAID (37.5 mg Carprofen per os every 12 h) as 
needed for pain relief. After 6 weeks, the length of daily walks 
was gradually increased 5–10  min per week until the patient 
could comfortably walk for 30  min without evidence of lame-
ness. A recheck ultrasound examination was performed 6 weeks 
after discharge, and an injection of platelet rich plasma (PRP) 
was performed at that time. Additional ultrasound and physical 
examinations are planned at 3-month intervals.
This case report uses a canine patient referred for a subtle 
forelimb lameness to illustrate the role of advanced imaging in 
a diagnostic plan and to recommend an innovative PET–CT 
imaging protocol, which identifies glucose uptake abnormalities 
and asymmetries useful in the diagnosis of muscular overuse, 
inflammation, or infection, in clinically lame canine patients.
BaCKGRoUND
Positron emission tomography imaging with 18F-FDG is 
widely known for its use in the diagnosis and tracking of 
primary and metastatic tumors via uptake and retention of 
the radiopharmaceutical by hypermetabolic cells (3). 18F-
FDG is also used to study the physiology of glucose uptake, 
metabolism, and muscle activity during and after exercise (4, 
5) or as a result of concurrent disease conditions (6, 7). The 
additional physiologic data gained from PET imaging are of 
particular interest to the Sports Medicine and Rehabilitation 
Service because they may aid in the diagnosis of subtle 
abnormalities that are not apparent on standard radiographic 
or US techniques. Additionally, it is not feasible to perform 
whole-body scanning with US or MR modalities, and similar 
to its extensive use in oncology, PET–CT can provide objective 
morphologic lesion localization and quantifiable functional 
measurements to document response to therapeutic interven-
tion in muscle groups that are difficult to evaluate through 
other means. Availability of integrated PET–CT equipment 
has increased in veterinary university and referral centers 
because of its universal application in cancer diagnosis and 
response to therapy. Although the half-life of fluorine-18 is 
short (110 min), commercial production for human medical 
procedures is common, which increases the logistic availabil-
ity of the radiopharmaceutical, and the short half-life allows 
release of the patient on the same day. In our geographic area, 
the availability and cost of 18F-FDG is reasonable because of 
its extensive use in human and veterinary oncology. Its use 
in human musculoskeletal diagnostic imaging and research 
is also increasing. Canine patients are commonly referred to 
our institution for shoulder and elbow pathology but also for 
lumbar spine or pelvic limb pain, creating the opportunity for 
PET as a complementary procedure, which adds physiological 
data to the CT findings.
eQUIpMeNt
Positron emission tomography–computed tomography imaging 
was performed with a Philips GEMINI TF Big Bore PET–CT 
system (Philips Healthcare, Koninklijke Philips Electronics N.V., 
Amsterdam). This system combines a 16-slice CT machine with 
time-of-flight (TOF) PET technology capable of 495-ps timing 
resolution and list mode reconstruction. The PET and CT gan-
tries have an 85-cm inner diameter with up to 60-cm diameter 
field of view.
pet–Ct IMaGING pRotoCoL
Immediately prior to premedication and induction of general 
anesthesia, the patient is leash-walked for a minimum of 15 min. 
Patient monitoring during the anesthetic episode includes: 
ECG, arterial pressure, capnography, pulse oximetry, ventila-
tion rate and quality, and urinary catheterization. The patient 
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is positioned on the PET–CT table in dorsal recumbency, and 
the table position is zeroed. 18F-FDG (5.2–6.3  MBq/kg) is 
injected via indwelling catheter in the cephalic or saphenous 
vein. The venous and arterial catheter locations are selected to 
specifically avoid the thoracic or pelvic limb area of interest 
noted in the patient history. Local radiation safety policies 
require that the 1-h radiopharmaceutical uptake time occurs 
in the PET–CT suite. After intravenous administration of the 
radiopharmaceutical, the patient’s vital signs and plane of 
anesthesia are monitored remotely from the shielded PET–CT 
control room.
At 20 min prior to PET acquisition (after 40 min of uptake 
time), a non-contrast helical CT series focused on the thoracic or 
pelvic limb area of interest is performed and reconstructed with 
1-mm bone and 2-mm standard filters in a 1024 × 1024 matrix. 
A non-contrast whole-body CT series immediately follows the 
focused series, and 5- and 2-mm (768 ×  768 matrix) standard 
reconstructions are created.
After 60  min of radiopharmaceutical uptake time, a 
whole-body PET acquisition using consecutive 8-cm beds 
with 1.5-min bed times is initiated. At the conclusion of the 
PET acquisition, an early venous phase contrast-enhanced 
whole-body CT is performed using a standard algorithm, with 
5- and 2-mm standard reconstructions as described in the non-
contrast series above. For the contrast-enhanced CT, 2 ml/kg 
of a non-ionic, iodinated contrast solution [iohexol 755  mg/
ml (equivalent to 350 mg of organic iodine), GE Healthcare] is 
administered via autoinjector at 2 ml/s followed by 1 ml/kg of 
0.9% NaCl at 2 ml/s. The CT scan begins after a 40- to 50-s delay 
based on patient heart rate.
post-sCaNNING pRoCeDURes
All images from each of the PET and CT acquisitions are trans-
ferred to the hospital picture archiving and communication sys-
tem and fused PET–CT images are viewed on a dedicated Philips 
IntelliSpace Portal workstation (v6.0.2.32500, 13 June 2014, 
Koninklijke Philips Electronics N.V.) for clinical interpretation. 
In our experience, the blue palette (cardiac) lookup table (LUT) 
significantly increases the conspicuity of radiopharmaceutical 
uptake in fused PET–CT images when compared to the red 
palette (thermal) LUT. The patient recovers from anesthesia 
in a dedicated nuclear medicine ward and segregated walking 
area with closed circuit television monitoring after extubation. 
Local radiation safety policies allow the patient to return to the 
client or other sections of the veterinary teaching hospital after 
reaching a survey meter reading of ≤20 μSv/h at the skin surface 
of the shoulder region. Abnormal PET–CT findings are further 
investigated with additional diagnostic imaging or at surgery 
(e.g., ultrasound, MRI, and arthroscopy).
DIsCUssIoN
The initial clinical observations confirmed a chronic, mild right 
thoracic limb lameness, but failed to localize the specific cause. A 
PET–CT was recommended and elected. Fused PET–CT images 
were evaluated in multiple, preset, and adjustable Hounsfield unit 
window levels and widths to identify abnormal areas of uptake 
or areas of asymmetric uptake in the skeletal muscles of the 
thoracic limbs, pelvic limbs, or axial regions of the patient. The 
three-dimensional PET maximum intensity projection (MIP) is 
helpful for orientation prior to detailed review of the data acquisi-
tions in two-dimensional transverse, sagittal, and dorsal planes or 
three-dimensional CT volume rendering (Figure 1).
Setting the PET overlay to display a narrow standardized 
uptake value (SUV) window width (0–5) is particularly important 
when searching for asymmetric radiopharmaceutical uptake in 
skeletal muscle because subtle areas of increased uptake must be 
conspicuous in comparison to the surrounding or contralateral 
normal tissues.
In this case, normal uptake of 18F-FDG was noted within the 
central nervous system, zygomatic and mandibular salivary glands, 
vocal folds, myocardium, and abdominal viscera, as well as normal 
excretion via the urinary tract (8–10) (Figure 1). On evaluation of 
the radionuclide uptake within the muscles of the thoracic limbs, 
asymmetrically IRU was identified in the FCU muscle of the 
right antebrachium with a maximum standardized uptake value 
(SUVmax) of 2.4, compared to the contralateral muscle with 1.0 
SUVmax (11) (Figures 2A–C). This finding is related to increased 
cellular metabolic activity and may be the result of compensatory 
overuse of the muscle, inflammation, or injury. IRU in a neoplastic 
cell results from unregulated increase in glucose transporters and 
dependence on glycolysis for energy production. Inflammation, 
injury, or increased use of glucose by non-neoplastic muscle cells 
causes IRU secondary to normal physiologic glycolysis in response 
to cell injury and repair mechanisms. Although iodinated contrast 
may increase the conspicuity of soft tissue injury in CT images as 
a result of neovascularization or extravasation from increased vas-
cular permeability, a change in the density, size, or enhancement 
may be inconspicuous or mild, as in this patient (12). Contrast 
enhancement and tissue density in CT images are affected by 
variability in the amount of neovascularization, vascular perme-
ability and edema in the lesion itself, and the timing of contrast 
administration. In this case, a diagnostic ultrasound examination 
identified two small hypoechoic areas within the muscle of the 
right FCU, just proximal to the insertion on the accessory carpal 
bone. Corresponding irregular and hypoechoic muscle fibers were 
also visible on long axis images (Figure 3). These findings were 
consistent with muscle tearing within the right FCU muscle and 
corresponded to the most intense region of radiopharmaceutical 
uptake on the PET–CT images (Figure 2B) (13, 14). The extent 
of IRU identified a larger area of affected FCU muscle, when 
compared to the small focus of CT contrast enhancement. At the 
recheck ultrasound examination 6 weeks after discharge, an intral-
esional injection of platelet-rich plasma (PRP) was performed to 
promote healing. Clinical use of PRP is becoming commonplace 
in both human and veterinary medicine for the treatment of mus-
culoskeletal injuries. The beneficial effects of PRP are attributed 
in part to growth factors released by activated platelets leading to 
neovascularization (15–18). Additional ultrasound and physical 
examinations to document the healing process are scheduled 
every 3 months.
There are unique challenges to overcome when conduct-
ing PET–CT imaging of veterinary patients, and attention to 
FIGURe 2 | pet–Ct images demonstrating increased 18F-FDG uptake 
in the right flexor carpi ulnaris muscle. (a) PET MIP, ventral view, red 
palette (thermal) lookup table (LUT). Normal radionuclide uptake is also 
present in the brain, zygomatic and mandibular salivary glands, and vocal 
folds. (B) PET–CT, ventral view, right antebrachium, blue palette (cardiac) 
LUT. (C) PET–CT, transverse view, blue palette (cardiac) LUT. Comparison of 
the right and left antebrachii at the level of the right flexor carpi ulnaris muscle 
injury. The right antebrachium is on the right of the image. The blue palette 
LUT increases lesion conspicuity when viewing fused images.
FIGURe 1 | Whole-body pet MIp with abnormal 18F-FDG uptake 
noted in right thoracic limb (red crosshairs). Normal radiopharmaceutical 
uptake in the brain, zygomatic and mandibular salivary glands, vocal folds, 
myocardium, abdominal viscera, and urinary tract is also present.
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certain details can maximize the quality of the data acquisi-
tion. A short period of mild muscular effort (leash walking) is 
recommended prior to anesthesia to increase the possibility of 
detecting asymmetric radiopharmaceutical uptake in individual 
muscles or muscle groups. However, strenuous muscle activity 
(e.g., focused strength training, sled pulling, or excessive physical 
effort) can result in IRU for 24–48 h after the event and upset the 
balance between detectable asymmetry versus induced normal 
physiologic uptake that masks underlying abnormal pathologic 
uptake. External monitoring instrumentation and intravenous 
and intra-arterial catheters are placed outside the thoracic 
or pelvic limb area of interest to avoid the possibility of beam 
hardening artifacts or IRU from inflammation or extravasation at 
the site of medication, iodinated contrast, or radiopharmaceuti-
cal injection. Using radiolucent, padded v-troughs, wedges, and 
blocks to position the patient in dorsal recumbency, with thoracic 
limbs moderately extended, elbows and paws parallel to one 
another, and pelvic limbs extended with stifles, and paws paral-
lel to one another will help to achieve bilateral symmetry. This 
also extends the spine axially to avoid curvature and allow better 
evaluation of the cervical and lumbosacral regions. Positioning 
the patient with the pelvic limbs first into the gantry allows the 
greatest access to the endotracheal tube, long ventilation tubes, 
anesthesia cart, and patient monitoring display screens (remotely 
viewed on closed circuit or wireless monitors in the CT control 
FIGURe 3 | sagittal ultrasound image of the muscle tear (red arrows) 
in the right flexor carpi ulnaris muscle just proximal to the accessory 
carpal bone (left side of image is distal).
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room) as the patient table travels more than 2 m in and out of 
the PET and CT gantries. This consistent and symmetric method 
of positioning also greatly assists in the assessment of ipsilateral 
and contralateral bone and soft tissue anatomical structures dur-
ing image evaluation, improving comparison and detection of 
abnormalities of radiopharmaceutical uptake, iodinated contrast 
enhancement, density, and size. An indwelling urinary catheter 
minimizes urinary bladder size, improving image interpretation 
in the caudal abdomen, and facilitates the removal of radioactive 
urine, protecting against contamination of the gantry and further 
decreasing patient exposure.
This PET–CT protocol is also consistent with the tenets 
of radiation safety and published nuclear medicine dosing 
recommendations. Local radiation safety policies require the 
radionuclide uptake time to occur in the PET–CT suite. All 
personnel wear body and ring badges, lab coats, gloves, and 
closed-toe shoes. The patient achieves a stable plane of general 
anesthesia prior to radiopharmaceutical administration, and 
remote monitoring equipment minimizes contact with the 
patient during the PET–CT data acquisition and anesthesia 
recovery time periods. The veterinary patient dose is in 
accordance with North American and European Association 
of Nuclear Medicine recommendations for human pediatric 
patients, further ensuring that the exposure to veterinary 
personnel will be minimized (19).
CoNCLUDING ReMaRKs
Integrated PET–CT is a significant diagnostic method, synergiz-
ing the localization and anatomic and physiologic data analysis 
tools of two advanced imaging modalities. Although primarily 
known for extensive use in the field of oncology, the application of 
18F-FDG imaging for the clinical evaluation and research of mus-
culoskeletal disease conditions and normal exercise physiology is 
increasing. The PET–CT imaging protocol recommended in this 
report was designed to significantly enhance a routine thoracic 
or pelvic limb CT examination and to identify areas of muscle, 
tendon, or ligament overuse, inflammation, or injury for further 
diagnostic procedures or definitive treatment. The 18F-FDG 
PET–CT added valuable physiologic and anatomic information 
to the diagnostic evaluation of this patient, which can also be 
used for objective evaluation of the healing process in serial 
examinations. Current efforts are aimed at the validation of this 
technique through demonstrated benefit to additional patients in 
the ongoing pilot study. PET–CT imaging is recommended after 
standard means of diagnosis have failed or when the specific 
physiologic information provided by a PET radiopharmaceutical 
may detect subtle metabolic abnormalities in the muscle, indicat-
ing compensatory overuse, inflammation, or injury. Continued 
tailoring of the PET acquisition and radiopharmaceutical 
parameters will allow for more detailed information gathering in 
the realm of exercise physiology. Future efforts will increase the 
objective PET–CT data available to more closely assess normal 
and abnormal physiology, unlocking a new frontier in the study 
of canine athletic injury and optimal performance.
aUtHoR CoNtRIBUtIoNs
This case report was designed and coordinated by KM, JH and FD 
to specifically introduce a novel imaging protocol and the reason-
ing behind its use in the diagnostic evaluation of canine patients 
with intermittent or subtle, undiagnosed lameness.
aCKNoWLeDGMeNts
This pilot study was inspired by the work of researchers study-
ing asymmetric glucose uptake and premature fatigability in 
leg muscles of Multiple Sclerosis patients in the Integrative 
Neurophysiology Laboratory, Department of Health and Exercise 
Science, Colorado State University (http://inplab.colostate.
edu/). Additional patient care and medical procedures other 
than PET–CT were performed by professional colleagues in the 
Veterinary Diagnostic Imaging, Small Animal Sports Medicine 
and Rehabilitation, and Small Animal Orthopedics services of the 
CSU Veterinary Teaching Hospital.
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